Supply chain transparency and the availability of essential medicines
Bull World Health Organ
.
2021 Apr 1;99(4):319-320.
doi: 10.2471/BLT.20.267724.
Epub 2021 Jan 21.
Authors
Christine Årdal
1
,
Enrico Baraldi
2
,
Peter Beyer
3
,
Yohann Lacotte
4
,
Dg Joakim Larsson
5
,
Marie-Cécile Ploy
4
,
John-Arne Røttingen
6
,
Ingrid Smith
7
Affiliations
1
Antimicrobial Resistance Centre, Norwegian Institute of Public Health, Postboks 222 Skøyen, 0213, Oslo, Norway.
2
Department of Civil and Industrial Engineering, Uppsala University, Uppsala, Sweden.
3
Department of Global Coordination and Partnership, World Health Organization, Geneva, Switzerland.
4
RESINFIT, University of Limoges, Limoges, France.
5
Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden.
6
Research Council of Norway, Lysaker, Norway.
7
Department of Research and Development, Haukeland University Hospital, Bergen, Norway.
PMID:
33953450
PMCID:
PMC8085627
DOI:
10.2471/BLT.20.267724
No abstract available
MeSH terms
Drugs, Essential* / supply & distribution
Health Services Accessibility
Humans
Substances
Drugs, Essential
Grants and funding
001/WHO_/World Health Organization/International